Clinical Trials in Catania, Catania

7 recruiting

Showing 17 of 7 trials

Recruiting
Phase 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma ( FL)
Genmab1,095 enrolled265 locationsNCT06191744
Recruiting

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

Non-small Cell Lung CancerPulmonary Stereotactic Radiotherapy
Istituto Clinico Humanitas150 enrolled11 locationsNCT07401615
Recruiting
Not Applicable

Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

Heart Failure With Reduced Ejection Fraction (HFrEF)Dilated Cardiomyopathy
Ancora Heart, Inc.400 enrolled132 locationsNCT04331769
Recruiting

Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

Cervical CancerLocally Advanced Cervical CancerRecurrent Cervical Cancer+1 more
MSD Italia S.r.l.200 enrolled11 locationsNCT06771193
Recruiting
Phase 2

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Breast Cancer
Fondazione Oncotech51 enrolled8 locationsNCT06259929
Recruiting

Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Marginal Zone Lymphoma (MZL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna59 enrolled15 locationsNCT06823960
Recruiting

An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

Diffuse Large B-Cell Lymphoma (DLBCL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna96 enrolled11 locationsNCT06782789